Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series. Issue 2 (April 2023)

• Record Type: Journal Article
• Authors: Broccoli, Alessandro; Argnani, Lisa; Coppola, Paolo Elia; Gentilini, Marianna; Bagnato, Gianmarco; Lolli, Ginevra; Carella, Matteo; Nanni, Laura; Morigi, Alice; Casadei, Beatrice; Pellegrini, Cinzia; Stefoni, Vittorio; Zinzani, Pier Luigi
• Is Part Of: Tumori. Volume 109:Issue 2(2023)
• Page Start: 249
• Page End: 252
• Publication Date: 2023-04
• Subjects: Brentuximab vedotin -- Hodgkin lymphoma -- relapsed -- refractory -- prolonged responses -- allogeneic stem cell transplantation; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916221090327
• Languages: English
• ISSNs: 0300-8916

Abstract

The follow-up of the pivotal trial and large case series reports of a proportion of patients, between 5% and 9%, with relapsed or refractory Hodgkin lymphoma failing autologous stem cell transplantation and treated with brentuximab vedotin, achieving and maintaining long lasting complete responses with no further treatment. Very long-term data on the outcomes of such patients are indeed underreported. Our institutional experience with patients meeting these characteristics and in continuous complete response for more than 5 years after brentuximab vedotin was reviewed. Five patients achieved a median duration of complete response of 7.4 (range 5.1-8.1) years, and none of them encountered disease relapse or received any subsequent consolidation, including allogeneic transplantation. A proportion of patients failing autologous transplantation and receiving subsequent brentuximab vedotin may reach a long-lasting complete response with no need of further treatment. These patients are therefore considered cured. The role of allogeneic transplantation in such patients is matter of debate.